National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Durvalumab (Imfinzi®)

Durvalumab (Imfinzi®) is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)  in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).


NCPE Assessment Process Ongoing
Rapid review commissioned 29/03/2019
Rapid review completed 29/04/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/05/2019
Pre-submission consultation with Applicant 10/06/2019
Submission received from Applicant 30/08/2019
Preliminary review sent to Applicant 20/12/2019
NCPE assessment re-commenced 30/01/2020
Factual accuracy sent to Applicant 16/04/2020
NCPE assessment re-commenced 24/04/2020
NCPE assessment completed 07/05/2020
NCPE assessment outcome The NCPE recommends that durvalumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.